New Phase 3 Data for TREMFYA®▼ (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, Show Consistent, High Levels of Skin Clearance Through Four Years in Adult Patients with Moderate to Severe Plaque Psoriasis | Johnson & Johnson

New Phase 3 Data for TREMFYA®▼ (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, Show Consistent, High Levels of Skin Clearance Through Four Years in Adult Patients with Moderate to Severe Plaque Psoriasis

06/15/2020

DownloadPDF 236 KB

Multimedia Files:

Questions? Please contact us:

investor-relations@its.jnj.com